Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M

Stemline Therapeutics, whose drug for a rare, aggressive type of acute leukemia was approved by the FDA about 18 months ago, has signed an acquisition deal with Italian biopharma Menarini Group.